Organization
Department of Interventional Oncology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
1 abstract
Abstract
Neoadjuvant immune-checkpoint blockade therapy combined with TACE for resectable hepatocellular carcinoma with high recurrence risk: A phase II, single-arm clinical trial (MORNING).Org: Center of Hepato-Pancreato-Biliary Surgery, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Department of Interventional Oncology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Department of Interventional Radiology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Clinical Trials Unit, Institute of Precision Medicine, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China,